Patents by Inventor Gerard Joseph OAKLEY, III

Gerard Joseph OAKLEY, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER WITH PDGFR ALPHA INHIBITORS
    Publication number: 20240132602
    Abstract: Methods for treating cancer patients with human platelet derived growth factor receptor alpha inhibiting compounds, in which the patient is identified as having a cancer that is human platelet derived growth factor receptor beta negative.
    Type: Application
    Filed: March 16, 2022
    Publication date: April 25, 2024
    Inventors: Gerard Joseph OAKLEY, III, Patrick Marshall PETERSON, Louis Frank STANCATO, Richard Anthony WALGREN
  • TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA
    Publication number: 20220296607
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
    Type: Application
    Filed: June 2, 2022
    Publication date: September 22, 2022
    Applicant: Eli Lilly and Company
    Inventors: Karim Adnane BENHADJI, Gerard Joseph OAKLEY, III
  • Targeted treatment of mature T-cell lymphoma
    Patent number: 11376259
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 5, 2022
    Assignee: Eli Lilly and Company
    Inventors: Karim Adnane Benhadji, Gerard Joseph Oakley, III
  • TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA
    Publication number: 20190231794
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
    Type: Application
    Filed: October 6, 2017
    Publication date: August 1, 2019
    Applicant: Eli Lilly and Company
    Inventors: Karim Adnane BENHADJI, Gerard Joseph OAKLEY, III